The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: an EORTC phase II study (08992)
- 28 February 2003
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (3) , 353-357
- https://doi.org/10.1016/s0959-8049(02)00668-8
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 15 references indexed in Scilit:
- Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2002
- Raltitrexed: current clinical status and future directionsAnnals of Oncology, 2002
- Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancerEuropean Journal Of Cancer, 2002
- Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbineSeminars in Oncology, 2002
- Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2002
- A phase II EORTC study of temozolomide in patients with malignant pleural mesotheliomaEuropean Journal Of Cancer, 2002
- Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesotheliomaEuropean Journal Of Cancer, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesotheliomaBritish Journal of Cancer, 1999
- A Proposed New International TNM Staging System for Malignant Pleural MesotheliomaChest, 1995